{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:09:21Z","timestamp":1790057361025,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajpc.2026.101778","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:23:22Z","timestamp":1785943402000},"page":"101778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment patterns in homozygous familial hypercholesterolemia: Undertreatment and delayed adoption of low-density lipoprotein receptor\u2013independent therapies"],"prefix":"10.1016","volume":"30","author":[{"given":"Dana J.","family":"Murdock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Godin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2026.101778_bib0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.atherosclerosis.2018.06.855","article-title":"Epidemiology of familial hypercholesterolaemia: community and clinical","volume":"277","author":"Vallejo-Vaz","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2026.101778_bib0002","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2026.101778_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacl.2026.01.011","article-title":"Update on familial hypercholesterolemia: an expert clinical consensus from the National Lipid Association","volume":"20","author":"Ahmad","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101778_bib0004","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2026.101778_bib0005","article-title":"Familial hypercholesterolemia: a literature review of the pathophysiology and current and novel treatments","volume":"15","author":"Suryawanshi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ajpc.2026.101778_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ajpc.2026.101778_bib0007","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2026.101778_bib0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5334\/gh.1316","article-title":"It is time to screen for homozygous familial hypercholesterolemia in the United States","volume":"19","author":"Gidding","year":"2024","journal-title":"Glob Heart"},{"key":"10.1016\/j.ajpc.2026.101778_bib0009","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-023-02764-y","article-title":"The effect of PCSK9 inhibitors on LDL-C target achievement in patients with homozygous familial hypercholesterolemia: a retrospective cohort analysis","volume":"41","author":"Alshahrani","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.ajpc.2026.101778_bib0010","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ajpc.2026.101778_bib0011","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2026.101778_bib0012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MED.0000000000000590","article-title":"Novel therapies for familial hypercholesterolemia","volume":"28","author":"Mohamed","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ajpc.2026.101778_bib0013","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the treatment of homozygous familial hypercholesterolemia","volume":"29","author":"Bajaj","year":"2022","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ajpc.2026.101778_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2026.101778_bib0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jacl.2024.11.004","article-title":"High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: a real-world study","volume":"19","author":"Gu","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101778_bib0016","unstructured":"Halli Demeter S, Godin R, Sexton S, Seeff-Charny A. Understanding the HoFH patient journey: insights on diagnosis and treatment from patient and physician interviews. Preventive Cardiovascular Nurses Association\u2019s 31st Annual Cardiovascular Nursing Symposium 2025."},{"key":"10.1016\/j.ajpc.2026.101778_bib0017","series-title":"JUXTAPID\u00ae (lomitapide) capsules, for oral use","year":"2026"},{"key":"10.1016\/j.ajpc.2026.101778_bib0018","series-title":"EVKEEZA\u2122 (evinacumab-dgnb) injection, for intravenous use","year":"2025"},{"key":"10.1016\/j.ajpc.2026.101778_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag357","article-title":"Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry","author":"Schonck","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2026.101778_bib0020","series-title":"The JUXTAPID\u00ae risk evaluation and mitigation strategy (REMS)","year":"2026"},{"key":"10.1016\/j.ajpc.2026.101778_bib0021","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpc.2026.101778_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2026.101778_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2026.120646","article-title":"Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype","volume":"414","author":"Mancini","year":"2026","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2026.101778_bib0024","first-page":"936","article-title":"Estimation of missed statin prescription use in an administrative claims dataset","volume":"23","author":"Wade","year":"2017","journal-title":"J Manage Care Spec Pharm"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:56:34Z","timestamp":1790056594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726003521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":24,"alternative-id":["S2666667726003521"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101778","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns in homozygous familial hypercholesterolemia: Undertreatment and delayed adoption of low-density lipoprotein receptor\u2013independent therapies","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101778"}}